HC Wainwright reissued their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report issued on Tuesday. They currently have a $9.00 price objective on the biotechnology company’s stock.
“Valuation and potential impediments to achieving it. We reiterate our Buy rating and $8.60 price target. Our price target is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, CAP-1002 in DMD patients. We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch.”,” HC Wainwright’s analyst commented.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Capricor Therapeutics from a hold rating to a sell rating in a report on Wednesday, August 15th. Maxim Group reiterated a buy rating and issued a $4.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, November 14th. Finally, TheStreet cut shares of Capricor Therapeutics from a c- rating to a d+ rating in a report on Monday, October 15th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has an average rating of Buy and an average price target of $4.83.
Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Capricor Therapeutics had a net margin of 24.75% and a negative return on equity of 159.36%. The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.90 million. As a group, sell-side analysts predict that Capricor Therapeutics will post -0.57 earnings per share for the current year.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Read More: Understanding the different types of bonds
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.